source
- Compass Therapeutics reports secondary endpoint data from pivotal biliary tract cancer trial, shares stock dropCompass Therapeutics announced new secondary‑endpoint results from its pivotal bispecific antibody trial in second‑line biliary tract cancer, a year after reporting a Phase 2/3 success. The additi…
- Oruka's yearly injectable shows 63% complete clearance in mid-stage psoriasis trialOruka Therapeutics reported results from a Phase 2 trial of its long-acting injectable, ORKA-001, in patients with plaque psoriasis. In the study, 63% of participants achieved complete skin cleara…